A Phase I Study of Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

Trial Profile

A Phase I Study of Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Alisertib (Primary) ; Sapanisertib (Primary)
  • Indications Anal cancer; Gynaecological cancer; Human papillomavirus infections; Oropharyngeal cancer; Penile cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Mar 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 22 Jul 2016 Planned primary completion date changed from 1 Aug 2021 to 1 Sep 2021.
    • 22 Jul 2016 Planned initiation date changed from 1 Aug 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top